Introduction
============

Acute infectious diarrhea (AID) is a commonly reported condition among outpatients, worldwide \[[@B1]\]. Several studies have demonstrated that antibiotic use is non-ideal for AID treatment, except in some cases of travelers\' diarrhea or severe AID. Since bacteria are the causative organisms in only some cases of acute diarrheal disease, several cases often show improvement without antibiotic use \[[@B1][@B2][@B3]\]. An epidemiological study reported that most cases of community-acquired diarrhea are caused by viral pathogens; therefore, antibiotic treatment would not shorten the overall duration \[[@B1]\]. However, antibiotics are used frequently for AID. Inappropriate antibiotic use can lead to increased antibiotic resistance and medical costs, while also causing antibiotic-associated adverse events. While data on gastrointestinal infections are being collected by the Korea Centers for Disease Control and Prevention, the current status of antibiotic prescription for AID has not been researched. Accordingly, the objective of this study was to identify the current rates of antibiotic use and prescriptions for AID among Korean adults.

Materials and Methods
=====================

This study used National Health Insurance claims data for the assessment of the current status of antibiotic use among Korean adults diagnosed with AID. The health insurance system in Korea is a public insurance system that covers all Korean citizens, and runs independently of healthcare providers and private insurance companies. In the National Health Insurance system, there is no discrimination in the provision of access to healthcare resources based on patients\' income levels \[[@B4]\]. This study targeted adults aged 18 years or older, and National Health Insurance data pertaining to claims for AID in the three previous years (January 2015 to December 2017) were obtained from the Health Insurance Review and Assessment Service (HIRA). Patients who were diagnosed for the first time in 2015 and for whom subsequent claims were made under the same diagnostic code in 2016 and/or 2017 were excluded. Accordingly, the actual analysis included only new claim cases pertaining to AID-related codes in 2016 and 2017.

The HIRA database consists of diagnoses coded using the Korean Classification of Disease (7th edition). Among the health insurance claims data, we included those regarding the infectious diarrhea-related codes, comprising A020 (*Salmonella* enteritis), A044 (other intestinal *Escherichia coli* infection), A045 (*Campylobacter* enteritis), A046 (enteritis due to *Yersinia enterocolitica*), A049 (bacterial intestinal infection, unspecified), A060 (acute amoebic dysentery), A079 (protozoal intestinal disease, unspecified), A080 (rotaviral enteritis), A081 (acute gastroenteropathy due to Norwalk agent), A082 (adenoviral enteritis), A0830 (other viral enteritis), A0831 (astroviral gastroenteritis), A0838 (other viral enteritis), A084 (viral intestinal infection, unspecified), A090 (other and unspecified gastroenteritis and colitis of infectious origin), and A099 (gastroenteritis and colitis of unspecified origin). Of the entries that contained the diagnostic codes listed above, those that also contained diagnostic codes for inflammatory diarrheal diseases, such as K50 (Crohn\'s disease \[regional enteritis\]), K51 (ulcerative colitis), K52 (other noninfective gastroenteritis and colitis), and K58 (irritable bowel syndrome), were excluded.

Regardless of the diagnostic code rank, cases that included any of the aforementioned codes in the entire diagnosis were included in the analysis. However, patients who underwent surgery during the period in which the claim was made for the diagnostic code were excluded. Inpatient cases for whom the aforementioned codes were entered on the first day of hospitalization were included, while those for whom diagnostic codes were entered during hospitalization were excluded. In addition, we included cases for which the specialty of the physician filing the claim was internal medicine, family medicine, emergency medicine, or general practice. The medical facilities were classified according to the system provided by the HIRA. Private clinics, hospitals, general hospitals, and tertiary care hospitals were defined as medical institutions with \<30 hospital beds, 30 -- 39 hospital beds, ≥100 hospital beds and 6 -- 9 divisions or departments, and ≥500 hospital beds and ≥20 divisions or departments, respectively.

This study used routinely collected National Health Insurance data for the purposes of insurance claims; thus, ethics approval was not required. All data were analyzed via a chi-square test and population ratio test using SAS Enterprise Guide version 6.1 (SAS Institute Inc., Cary, NC, USA).

Results
=======

Claims were filed for a total of 2,494,737 patients with infectious diarrhea between 2015 and 2017. After excluding 881,680 patients for whom multiple claims were filed for the same diagnostic code in 2015, a total of 1,613,057 patients were included in the analysis (840,443 and 772,614 patients were diagnosed for the first time in 2016 and 2017, respectively). The total numbers of men and women were 767,606 (47.6%) and 845,451 (52.4%), respectively. [Figure 1](#F1){ref-type="fig"} shows the distribution of patients\' ages and sex ratio.

![Distribution of adult patients with infectious diarrhea, according to age group and sex.](ic-51-295-g001){#F1}

Antibiotic usage rate
---------------------

In our study population, 752,536 (46.7%) patients used antibiotics.

### 1. Antibiotic usage rate by age group {#sec1}

The antibiotic usage rates in the 18 -- 19, 20 -- 29, 30 -- 39, 40 -- 49, 50 -- 59, 60 -- 69, 70 -- 79, and ≥80 year age groups were 43.6%, 47.6%, 46.6%, 45.3%, 46.6%, 48.0%, 48.9%, and 51.0%, respectively, indicating that the antibiotic usage rate was higher in the older age groups. Using a cut-off age of 65 years, the numbers of those aged \<65 and ≥65 years who did not use antibiotics were 791,814 (53.6%) and 68,707 (50.6%), respectively, indicating a higher usage rate among those aged ≥65 years.

### 2. Antibiotic prescription rate by medical facility type {#sec2}

[Figure 2](#F2){ref-type="fig"} shows the antibiotic prescription rate by medical institution type. The results showed that the antibiotic prescription rate was higher in private clinics and hospitals than in tertiary care hospitals and general hospitals.

![Frequency of antibiotic prescription for patients with infectious diarrhea, according to medical facility type.](ic-51-295-g002){#F2}

### 3. Antibiotic prescription rate by region {#sec3}

[Figure 3](#F3){ref-type="fig"} shows the distribution of patients with AID, and that of those who did or did not use antibiotics, by region. The highest number of patients visited facilities in Seoul and Gyeonggi-do, and the proportions of patients who used antibiotics in these places were 47.8% and 42.8%, respectively. The regions with antibiotic usage rates exceeding 50% were Gwangju (57.4%), Jeollabuk-do (61.0%), Jeju-do (57.0%), Chungcheongbuk-do (53.4%), and Jeollanam-do (52.0%). Incheon (38.8%) and Sejong (38.1%) showed relatively low antibiotic usage rates.

![Use of antimicrobial agents among adults with infectious diarrhea, by region.](ic-51-295-g003){#F3}

Frequency and duration of antibiotic use
----------------------------------------

[Table 1](#T1){ref-type="table"} shows the frequency and duration of use by antibiotic class. No antibiotic was used exclusively and cases in which two or more antibiotics were used simultaneously were also included. The fluoroquinolone class of antibiotics (n = 276,704, 29.8%) and rifaximin (n=249,012, 26.8%) were most frequently used. Of the 69,194 cases that included all β-lactam/β-lactamase inhibitors and penicillin-class antibiotics, amoxicillin/clavulanate (57.3%) was the most frequently used, while amoxicillin alone was used in 27.7% of cases. Piperacillin/tazobactam and ampicillin/sulbactam were used in 3.6% and 3.4% of cases, respectively. Among the fluoroquinolone class of antibiotics, ciprofloxacin was the most frequently used (70.4%); levofloxacin (6.8%) and moxifloxacin (0.4%) were also used. Among the macrolide class of antibiotics (n=38,653, 4.2%), clarithromycin (37.0%), roxithromycin (24.4%), and azithromycin (AZM) (7.9%) were the most commonly noted. Oral antibiotics were more frequently used compared with intravenous antibiotics, except for clindamycin. [Table 2](#T2){ref-type="table"} shows the frequency and duration of use of combination antibiotic regimens. The fluoroquinolone or cephalosporin class of antibiotics was the most frequently used in combination with aminoglycosides.

###### Frequency and duration of antibiotic prescription for patients with infectious diarrhea

![](ic-51-295-i001)

  Antibiotics                       Frequency, n (%)   Duration, days (mean ± SD)   Route of administration   Age group   Medical facility type   Patient status                                                                                    
  --------------------------------- ------------------ ---------------------------- ------------------------- ----------- ----------------------- ---------------- --------------- --------------- --------------- ---------------- --------------- ----------------
  4th generation cephalosporins     214 (0.0)          12.08 ± 8.75                 214                                   105 (0.0)               109 (0.1)        64 (0.3)        129 (0.1)       21 (0.0)        0 (0.0)          205 (0.2)       9 (0.0)
  3rd generation cephalosporins     67,335 (7.3)       6.02 ± 5.45                  38,102                    45,418      57,125 (6.8)            10,210 (11.0)    4,101 (18.2)    39,161 (23.3)   14,465 (13.4)   9,608 (1.5)      33,098 (29.3)   34,237 (4.2)
  2nd generation cephalosporins     85,528 (9.2)       3.84 ± 3.76                  3,421                     83,081      78,521 (9.4)            7,007 (7.6)      165 (0.7)       7,156 (4.3)     9,131 (8.5)     69,076 (11.0)    4,164 (3.7)     81,364 (10.0)
  1st generation cephalosporins     16,953 (1.8)       3.39 ± 3.41                  5,073                     12,131      15,023 (1.8)            1,930 (2.1)      174 (0.8)       1,809 (1.1)     2,290 (2.1)     12,680 (2.0)     2,121 (1.9)     14,832 (1.8)
  Fluoroquinolones                  276,704 (29.8)     4.98 ± 5.99                  38,828                    264,741     250,621 (30.0)          26,083 (28.1)    12,099 (53.7)   60,371 (35.9)   36,436 (33.8)   167,798 (26.6)   37,274 (33.0)   239,430 (29.4)
  Aminoglycosides                   32,944 (3.6)       4.48 ± 6.91                  32,944                                29,097 (3.5)            3,847 (4.1)      63 (0.3)        2,552 (1.5)     4,978 (4.6)     25,351 (4.0)     4,026 (3.6)     28,918 (3.6)
  Macrolides                        38,653 (4.2)       11.55 ± 12.27                14,822                    28,653      32,902 (3.9)            5,751 (6.2)      2,699 (12.0)    15,142 (9.0)    7,499 (7.0)     13,313 (2.1)     15,189 (13.4)   23,464 (2.9)
  β-lactam/β-lactamase inhibitors   49,186 (5.3)       5.35 ± 6.22                  6,018                     44,379      44,227 (5.3)            4,959 (5.3)      741 (3.3)       5,053 (3.0)     5,418 (5.0)     37,974 (6.0)     5,031 (4.5)     44,155 (5.4)
  Metronidazole                     26,169 (2.8)       9.29 ± 12.73                 287                       26,008      23,197 (2.8)            2,972 (3.2)      575 (2.6)       2,721 (1.6)     2,067 (1.9)     20,806 (3.3)     1,960 (1.7)     24,209 (3.0)
  Tetracycline                      4,469 (0.5)        12.29 ± 12.74                3                         4,467       3,826 (0.5)             643 (0.7)        261 (1.2)       781 (0.5)       584 (0.5)       2,843 (0.5)      827 (0.7)       3,642 (0.5)
  Carbapenems                       1,243 (0.1)        19.43 ± 16.58                1,243                                 465 (0.1)               778 (0.8)        161 (0.7)       786 (0.5)       291 (0.3)       5 (0.0)          1,200 (1.1)     43 (0.0)
  Glycopeptides                     834 (0.1)          18.53 ± 23.73                241                       604         541 (0.1)               293 (0.3)        143 (0.6)       569 (0.3)       66 (0.1)        56 (0.0)         429 (0.4)       405 (0.1)
  Trimethoprim/sulfamethoxazole     51,405 (5.5)       3.77 ± 4.85                  30                        51,395      46,885 (5.6)            4,520 (4.9)      89 (0.4)        1,702 (1.0)     1,422 (1.3)     48,192 (7.7)     606 (0.5)       50,799 (6.2)
  Clindamycin                       588 (0.1)          9.69 ± 13.71                 495                       176         460 (0.1)               128 (0.1)        33 (0.2)        119 (0.1)       135 (0.1)       301 (0.1)        179 (0.2)       409 (0.1)
  Penicillins                       20,008 (2.2)       7.44 ± 9.57                  191                       19,835      17,872 (2.1)            2,136 (2.3)      244 (1.1)       1,279 (0.8)     1,593 (1.5)     16,892 (2.7)     369 (0.3)       19,639 (2.4)
  Rifaximin                         249,012 (26.8)     4.56 ± 6.22                                            249,012     228,567 (27.4)          20,445 (22.0)    888 (3.9)       28,602 (17.0)   20,988 (19.5)   198,534 (31.5)   6,235 (5.5)     242,777 (29.8)
  Others^a^                         7,363 (0.8)        5.66 ± 10.10                 7,313                     50          6,342 (0.8)             1,021 (1.1)      21 (0.1)        230 (0.1)       383 (0.4)       6,729 (1.1)      179 (0.2)       7,184 (0.9)
  Total                             928,608 (100)                                                                         835,776 (100)           92,832 (100)     22,521 (100)    168,162 (100)   107,767 (100)   630,158 (100)    113,092 (100)   815,516 (100)

^a^Colistin, monobactams, fosfomycin, lincosamide, and linezolid.

No antibiotic was used exclusively; we included cases of concurrent use.

In the comparison by age and medical facility type, all antibiotics showed a statistically significant difference (*P* \<0.001).

In the comparison between inpatients/outpatients, all the items, except in the case of glycopeptides (*P* = 0.41), showed statistically significant differences (*P* \<0.001).

SD, standard deviation; IV, intravenous; PO, oral.

###### Prescription of antibiotic combination regimens for patients with infectious diarrhea

![](ic-51-295-i002)

  Antibiotics                                         Frequency, n   Duration, days (mean ± SD)
  --------------------------------------------------- -------------- ----------------------------
  Cephalosporin + metronidazole                       2,264          8.96 ± 7.38
  Fluoroquinolone + metronidazole                     901            17.84 ± 17.07
  Carbapenem + metronidazole                          81             23.35 ± 15.90
  Penicillin + metronidazole                          3,011          10.07 ± 5.95
  β-lactam/β-lactamase inhibitors + metronidazole     715            10.63 ± 10.15
  Cephalosporin + aminoglycosides                     9,828          5.13 ± 5.33
  Aminoglycosides + metronidazole                     795            6.31 ± 9.48
  β-lactam/β-lactamase inhibitors + aminoglycosides   3,432          6.53 ± 9.98
  Fluoroquinolones + aminoglycosides                  11,447         3.75 ± 6.65
  Cephalosporin + clindamycin                         227            10.32 ± 8.28
  Fluoroquinolones + clindamycin                      105            18.35 ± 14.96

### 1. Current status of antibiotic use by age group {#sec1___1}

[Table 1](#T1){ref-type="table"} shows the current status of antibiotic use among patients aged \<65 and ≥65 years. Statistically significant differences were observed among all the antibiotics used (*P* \<0.001). Patients aged ≥65 years showed a higher frequency of use of broad-spectrum, high-priced antibiotics, such as third and fourth-generation cephalosporins, carbapenems, and glycopeptides. However, they showed a relatively lower frequency of use of fluoroquinolones, rifaximin, second-generation cephalosporins, and trimethoprim/sulfamethoxazole, compared with patients aged \<65 years.

### 2. Current status of antibiotic use by medical facility type {#sec2___1}

[Tables 1](#T1){ref-type="table"} and [3](#T3){ref-type="table"} show the current status of antibiotic use by medical facility type. All the items showed statistically significant differences (*P* \<0.001). The fluoroquinolone class of antibiotics was most frequently prescribed in tertiary care hospitals, followed by macrolides. Third-generation cephalosporins were most frequently used in general hospitals. Private clinics used second-generation cephalosporins and rifaximin more frequently than did other medical facilities; in contrast, third-generation cephalosporins were used less frequently. Aminoglycosides were more frequently used in private clinics than in tertiary care hospitals or general hospitals. However, aminoglycosides were not frequently used in combination regimens, indicating that private clinics often used aminoglycosides alone.

###### Prescription of antibiotic combination regimens for patients with infectious diarrhea, according to the type of medical facility

![](ic-51-295-i003)

  Antibiotics                                         Frequency, n (%)   Tertiary care hospital, n (%)   General hospital, n (%)   Hospital, n (%)   Private clinic, n (%)
  --------------------------------------------------- ------------------ ------------------------------- ------------------------- ----------------- -----------------------
  Cephalosporin + metronidazole                       2,264 (0.3)        260 (1.8)                       1,123 (0.9)               519 (0.6)         362 (0.1)
  Fluoroquinolone + metronidazole                     901 (0.1)          87 (0.6)                        444 (0.4)                 236 (0.3)         134 (0.0)
  Carbapenem + metronidazole                          81 (0.0)           10 (0.1)                        52 (0.0)                  18 (0.0)          1 (0.0)
  Penicillin + metronidazole                          3,011 (0.4)        136 (1.0)                       828 (0.7)                 422 (0.5)         1,625 (0.3)
  β-lactam/β-lactamase inhibitors + metronidazole     715 (0.1)          56 (0.4)                        273 (0.2)                 171 (0.2)         215 (0.0)
  Cephalosporin + aminoglycosides                     9,828 (1.3)        58 (0.4)                        1,960 (1.6)               2,205 (2.7)       5,605 (1.1)
  Aminoglycosides + metronidazole                     795 (0.1)          5 (0.0)                         60 (0.0)                  156 (0.2)         574 (0.1)
  β-lactam/β-lactamase inhibitors + aminoglycosides   3,432 (0.5)        30 (0.2)                        440 (0.4)                 636 (0.8)         2,326 (0.4)
  Fluoroquinolones + aminoglycosides                  11,447 (1.5)       149 (1.1)                       1,083 (0.9)               1,799 (2.2)       8,416 (1.6)
  Cephalosporin + clindamycin                         227 (0.0)          28 (0.2)                        104 (0.1)                 52 (0.1)          43 (0.0)
  Fluoroquinolones + clindamycin                      105 (0.0)          15 (0.1)                        53 (0.0)                  27 (0.0)          10 (0.0)
  Other regimens                                      719,730 (95.6)     13,297 (94.1)                   116,857 (94.8)            75,936 (92.4)     513,640 (96.4)
  Total                                               752,536 (100)      14,131 (100)                    123,277 (100)             82,177 (100)      532,951 (100)

Other regimens: including patients who received monotherapy and other combination therapies.

All antibiotics showed statistically significant differences (*P* \<0.001).

### 3. Current status of antibiotic use by patient status (inpatient versus outpatient) {#sec3___1}

Among inpatients, 56,275 of 90,380 patients (62.3%) used antibiotics, while 696,261 of 1,522,677 outpatients (45.7%) used antibiotics. [Table 1](#T1){ref-type="table"} shows the current status of antibiotic use among inpatients and outpatients. All items, apart from those with glycopeptides (*P* = 0.41), showed statistically significant differences (*P* \<0.001). Compared to outpatients, inpatients used third-generation cephalosporins more frequently. Inpatients also had a higher frequency of macrolide, carbapenem, and glycopeptide use than outpatients did. Outpatients used second-generation cephalosporins, metronidazole, trimethoprim/sulfamethoxazole, penicillin-class antibiotics, and rifaximin more frequently.

Discussion
==========

The results of this study showed that approximately half of all patients used antibiotics and that various classes of antibiotics other than those recommended in the treatment guidelines were also frequently used. The treatment guidelines for AID that have been published in Korea include the Clinical Guideline for the Diagnosis and Treatment of Gastrointestinal Infections that was published in 2010 \[[@B3]\] and revised in 2019 \[[@B5]\]. Both guidelines recommend the use of antibiotics for travelers\' diarrhea or diarrheal disease with moderate-to-severe symptoms \[[@B3][@B5]\]. The guidelines also recommend the use of fluoroquinolones, AZM, or rifaximin \[[@B3][@B5]\]. The findings of the present study showed that various types of antibiotics are currently being used for AID in Korea, with fluoroquinolones and rifaximin showing the highest usage rates, while AZM showed a low frequency of use.

According to a report published by the Korea Centers for Disease Control and Prevention in 2017 on reported culture-positive cases of gastrointestinal infection in Korea, viral and bacterial infections accounted for 59% and 40.5% of all cases, respectively. In decreasing order of frequency, the causative pathogens that have been reported include *Salmonella, Clostridium perfringens*, and *Campylobacter* \[[@B6]\]. Although fluoroquinolones, such as ciprofloxacin, are recommended as empiric antibiotics, macrolides, such as AZM, are recommended for *Campylobacter* infections due to the increasing trend of resistance to fluoroquinolones \[[@B7][@B8][@B9][@B10]\]. Rifaximin is a safe drug, the efficacy of which is similar to that of fluoroquinolones; thus, its use has increased in recent times \[[@B11]\].

However, most patients with acute watery diarrhea do not require antibiotic therapy \[[@B5]\]. In most cases, the cause is viral, and even in cases caused by bacteria, most patients show improvements naturally without any specific treatment \[[@B2][@B12][@B13]\]. In the present study, antibiotics were used in approximately 47% of AID cases, suggesting that unnecessary antibiotics were used too often. In particular, the antibiotic prescription rate was higher in private clinics than in tertiary care hospitals. This is believed to be due to the fact that private clinics tend to have limited laboratory tests, and experience a greater level of pressure when patients do not show improvements in symptoms within a short period of time.

With respect to the current status of use of combination antibiotic regimens, cephalosporins or fluoroquinolones were often combined with aminoglycosides. The use of such combination antibiotic regimens may be helpful in the treatment of moderate-to-severe Gram-negative infections, but the use of aminoglycosides is not generally recommended for simple cases of AID \[[@B2][@B14]\].

In the present study, patients aged ≥65 years used antibiotics more frequently, which might be attributable to the fact that older patients typically have a higher severity of AID and consequently a higher mortality rate \[[@B15]\]. The average length of hospital stay among patients aged ≥75 years with diarrheal disease was found to be 7.4 days, which was approximately 3 days longer than the 4.1 days observed among patients aged 20 -- 49 years \[[@B16]\].

The present study had some limitations. First, we did not consider the exact diagnosis and clinical features of individual patients, and our analyses were based on secondary data obtained from HIRA that covers the entire population. Second, the AID-related diagnostic codes included main diagnoses and sub-diagnoses, and only a small number of patients were excluded; however, we cannot deny that duplicate patients with other diseases could be present. Third, since there is no separate diagnostic code for travelers\' diarrhea, patients with travelers\' diarrhea could not be assessed separately. Fourth, there is a lack of research data that can be used to compare the prevalence of AID and antibiotic usage rates for validity testing. Fifth, there may have been cases in which diagnostic codes unrelated to the actual patient diagnosis may have been entered to avoid cutbacks on healthcare use claims by the HIRA; however, such cases could not be excluded since the medical records of the patients could not be checked.

Despite these limitations, the present study is significant in that, to the best of our knowledge, it is the first to investigate the current status of antibiotic prescriptions for AID in Korea. In our study, we found that about half of AID patients received prescriptions for antibiotics, against the recommendations of the AID guidelines. Also, the study describes the recent epidemiology of AID in Korea.

In conclusion, the present study demonstrates a disparity in the rates of antibiotic use in current clinical practice and those mentioned in current guidelines for AID in Korea. The findings also indicate the need for each medical facility to review the appropriateness of the use of antibiotics for AID treatment and educate clinicians on the proper use of antibiotics in accordance with existing guidelines. Future studies should focus on the clinical features of patients and analysis of causative pathogens.
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